Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly TAS-102 plus bevacizumab in metastatic colorectal cancer (BiTS Study)
jRCTs051180184Phase 2Completed
- Sponsor
- Epidemiological and Clinical Research Information Network
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC), sponsored by Epidemiological and Clinical Research Information Network. Primary endpoints: Maximum tolerated dose (MTD) and 16-week progression-free survival (PFS) rate. Started Oct 2017; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs051180184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180184.